July 22, 2026

Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

read more →

PRNewswire

May 26, 2026

Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout

read more →

BioWorld

July 23, 2026

Financings for July 23, 2026

read more →

Endpoints News

July 22, 2026

Crystalys gets $130M to take Sobi-rivaling gout drug to market

read more →